FDA-Approved APHEXDA® (motixafortide)
Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following …
About APHEXDA | APHEXDA® (motixafortide)
Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following …
APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and …
For Patients | FDA-Approved APHEXDA® (motixafortide)
APHEXDA is a prescription medication used with filgrastim (G‑CSF) to move hematopoietic stem cells from the bone marrow to the peripheral blood for collection and subsequent autologous …
Stem Cell Mobilization | APHEXDA® (motixafortide)
Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following …
APHEXDA is a prescription medication used with filgrastim (G-CSF) to move hematopoietic stem cells from the bone marrow to the peripheral blood for collection and subsequent autologous …
Patient and HCP Support I APHEXDA® (motixafortide)
APHEXDA resources for patients and HCPs, including access and financial support, downloads, and FAQs. See Important Safety Information. This site is intended for US healthcare …
Dosing & Administration I APHEXDA® (motixafortide)
Patients with MM need 1 dose of APHEXDA + daily filgrastim for up to 2 sessions of apheresis stem cell collection. Learn dosing schedule and more. See Important Safety Information.
APHEXDA is indicated in combination with filgrastim* to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with …
Contact a Representative I APHEXDA® (motixafortide)
Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following …